Abstract
This study characterized a new signalling pathway in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-triggered lymphoma. The authors showed that the transcription factors JUN and JUNB promote lymphoma development and tumour dissemination through transcriptional regulation of platelet-derived growth factor receptor B (PDGFRB). Inhibition of PDGFRB with imatinib prolonged the survival of NPM-ALK transgenic mice and increased the efficacy of the ALK-specific inhibitor crizotinib in transplanted NPM-ALK tumours. In a patient with refractory late-stage NPM-ALK-positive lymphoma, imatinib produced a rapid, complete and sustained remission.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
